Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

BofA lowered the firm’s price target on Apellis (APLS) to $47 from $61 and keeps a Buy rating on the shares after the company reported ...

H.C. Wainwright lowered the firm’s price target on Apellis (APLS) to $57 from $83 and keeps a Buy rating on the shares post the Q3 ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...